RVMD News and Press, Revolution Medicines Inc. From 04/13/23

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chair...

REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American As...

2023-04-05 13:10:09 ET Summary The month of March had a couple of very interesting insider purchases. In this article, we discuss some of the biggest insider purchases by value. In addition, we will take a look into 2 companies more in-depth, which we found particularly intere...

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the closing of its underwritten public offering of 15,681,818 shares of common stock at a p...

REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 13,636,364 shares of common stock at a pu...

Revolution Medicines ( NASDAQ: RVMD ) on Wednesday announced that it has commenced an underwritten public offering to sell up to $300 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. The company also intends to gra...

Revolution Medicines, Inc. (RVMD) Q4 2022 Earnings Conference Call February 27, 2023 04:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman, President and Chief Executive Officer Steve Kelsey - President of Research and Devel...

The following slide deck was published by Revolution Medicines, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Revolution Medicines, Inc. 2022 Q4 - Results - Earnings Call Presentation

Revolution Medicines press release ( NASDAQ: RVMD ): Q4 GAAP EPS of -$0.63 beats by $0.18 . Revenue of $15.33M (+62.1% Y/Y) beats by $7.53M . Financial Guidance Revolution Medicines expects full year 2023 GAAP net loss to be between $335 and $365 million, whi...

Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RAS MULTI ) and RMC-6291 (KRAS G12C ) expected in 2023 RMC-9805 (KRAS G1 2D ) expected to begin clinica...